| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 9, 2023 |
| Accession Number: | 0001385508-23-000095 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2021 | $42.00 | Outperform | Oppenheimer |
15-12G - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)
Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (ORIG-1) with active ingredient NALMEFENE has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form
For Immediate Release: May 22, 2023 Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use. “The agency continues to advance the FDA
Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (nalmefene) (ORIG-1) with active ingredient OPVEE (nalmefene) has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form
Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press
CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV). Following the expiration of the waiti
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute that enables the FTC and Department of Justice (DOJ) to review proposed merger transactions by requiring the parties to observe a waiting period before closing their transaction. Completion of the tr
Oppenheimer initiated coverage of Opiant Pharmaceuticals with a rating of Outperform and set a new price target of $42.00
4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)
4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)